Prostate Cancer Upgrading Reference Set
Lay Description
Research repository designed to establish prostate cancer upgrading reference set and development of a risk prediction tool. Repository will include clinical information and biologics on a cohort of 240 men, to predict presence of high grade cancer at time of prostatectomy (removal of prostate) among patients with a low grade cancer diagnosis at time of biopsy.
Category
- IRB Number
- 20140367HU
- NCT Number
- NCT02189486
- Open to Enrollment
- Yes
Eligibility
- Eligible Ages
- Between 35 Years and 99 Years
- Eligible Genders
- Male
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Prostate cancer, confirmed on prostate biopsy, within two years of scheduled radical prostatectomy.
- Prostate cancer must be graded as Gleason 3+3 on the biopsy immediately prior to radical prostatectomy. (Secondary eligibility will be established on central review of pathology slides, and blocks if available, at Cornell Central Pathology Laboratory to confirm eligibility.)
- Prostate cancer may have been detected on prior biopsy as well but must not be greater than Gleason 3+3. (Also requires Central Pathology Laboratory review.)
- Slides must be available for Central Pathology Laboratory review on any biopsy showing prostate cancer. FFPE Blocks may also be requested if available.
- Patient must have selected radical prostatectomy as treatment for prostate cancer.
- Signed informed consent.
- Blocks and/or slides from prostate biopsy and from radical prostatectomy must be available for analysis by Central Pathology laboratory.
- Willingness to provide long-term follow-up information regarding additional treatments and cancer status.
- Willingness to provide blood and urine specimens prior to radical prostatectomy for placement in the EDRN Upgrading Reference Set repository.
- Willingness to provide demographic and clinical information related to prostate cancer and prostate cancer risk (e.g., race/ethnicity, family history of prostate cancer).
Exclusion Criteria
- Gleason score greater than 3+3 on any prior prostate biopsy.
- Any treatment other than radical prostatectomy planned for prostate cancer.
- Prior treatment of the prostate with androgen deprivation, radiation, or other cytotoxic chemotherapy.
Study Design
Arm Groups
Study Contact
Austen Clark
(210) 450-8688
clarka5@uthscsa.edu
Robin Leach
(210) 567-6947
leach@uthscsa.edu
Ian Thompson
(210) 567-5643
thompsoni@uthscsa.edu
Brandi Weaver
(210) 567-0158
weaverb@uthscsa.edu
Principal Investigator
Ian Thompson